Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursions RNA Foundation Model
Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will license Recursions RNA Foundation Model. Tempus and Recursion have...